BioCryst Pharmaceuticals is a biotechnology company that develops novel, oral, and small-molecule medicines. It markets peramivir injection for the treatment of acute uncomplicated influenza and ORLADEYO to treat hereditary angioedema. The company is also developing BCX9930, BCX9250, and Galidesivir for various diseases. It has collaborations and in-license relationships with several organizations. BioCryst Pharmaceuticals was founded in 1986 and is headquartered in Durham, North Carolina.